Administrative/Regulatory,
Health Care & Hospital Law
Jan. 10, 2018
SB 17: Drug price transparency rules
Senate Bill 17 requires pharmaceutical manufacturers that have a wholesale acquisition cost of more than $40 for a course of therapy to give 60 days' notice to state and health insurers if they plan to raise the price of a medication by 16 percent or more over a two-year period. It also requires pharmaceutical companies to justify the increased prices.
Michael L. Fuller
Partner
Knobbe Martens Olson & Bear LLP
Email: mfuller@kmob.com
Michael is co-managing partner of the San Diego office and chair of the firm's biotechnology practice group. He specializes in IP matters relating to biotech and bioinformatics innovations.
Daniel A. Kamkar
Associate
Knobbe Martens Olson & Bear LLP
Email: daniel.kamkar@knobbe.com
Daniel is an associate in the San Diego office. He assists various clients in a wide range of technological fields including pharmaceuticals, clean energy, polymer sciences, lasers and other areas of chemistry and physics.
On Oct. 9, 2017, Gov. Jerry Brown signed drug price transparency bill Senate Bill 17 into law. This law requires pharmaceutical manufacturers that have a wholesale acquisition cost of more than $40 for a course of therapy to give 60 days' notice to state and health insurers if they plan to raise the price of a medication by 16 percent or more over a two-year period. SB 17 also requires pharmaceutical companies to justify the increased prices. Under SB 17, "pharmaceuti...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In